Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
The type of leadership Americans need now
19/09/2025
GST cuts, Fed rate action spark market optimism : Alok Agarwal
19/09/2025
Adani Power share price target at Rs 818 : 3 reasons the stock is up 9%
19/09/2025
JSW Energy shares up 3%, rise for 2nd straight session : Here’s why
19/09/2025
Gold price steady after Fed rate cut, rebound from lows to open at Rs 1,09,365/10 g. Check key levels to watch
19/09/2025
Texmaco Rail & Engineering shares rally 4% on Rs 87 crore order win
19/09/2025
